<DOC>
	<DOCNO>NCT01530022</DOCNO>
	<brief_summary>The primary objective Phase 1 crossover study evaluate neuropsychological effect Lacosamide ( LCM ) compare Carbamazepine Immediate Release ( CBZ-IR ) administration healthy subject . Safety , tolerability , pharmacokinetic data also collect .</brief_summary>
	<brief_title>Crossover Study Neuropsychological Effects Lacosamide Carbamazepine Immediate Release Healthy Subjects</brief_title>
	<detailed_description>Approximately 50 subject multiple site crossover receive treatment ( lacosamide [ LCM ] carbamazepine immediate release [ CBZ-IR ] ) randomize order 2 study treatment period ( Treatment Period 1 Treatment Period 2 ) . A Screening Visit conduct evaluate subject eligibility enrollment study . Eligible subject return 21 day Screening Visit begin Treatment Period 1 . During Visit 2 , eligible subject randomize receive either LCM 300 mg/day CBZ-IR 600 mg/day . Subjects treat first randomize Antiepileptic Drug ( AED ) 6 week ( Titration Period [ 21 day ] Maintenance Period [ 21 day ] ) . Subjects complete 28-day Taper/Washout Period , first AED taper 4 day follow 24-day Washout Period , subject receive AED . Upon completion Taper/Washout Period , subject begin Treatment Period 2.The procedure assessment Treatment Period 1 repeat Treatment Period 2 ( duration treatment ) .</detailed_description>
	<mesh_term>Lacosamide</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Subjects 18 55 year age ( inclusive ) Subjects Body Mass Index ( BMI ) 18 35 kg/m^2 ( inclusive ) Subjects must generally good health clinically relevant health condition Subject previously randomize study subject receive LCM CBZ Subjects may currently participate participate past 30 day clinical drug device study Subjects may history drug alcohol abuse within last 2 year Subjects may consume 40 g alcohol per day Females pregnant nursing ineligible ; female childbearing potential must agree adhere protocol conception guideline Subjects may score â‰¤ 70 Peabody Picture Vocabulary Test ( PPVT ) Subjects lifetime history suicide attempt suicidal ideation past 6 month may participate Subjects diet deviate notably normal amount protein , carbohydrate , fat , judge investigator ineligible participate Subjects may consume 600 mg caffeine/day Subjects may smoke 10 cigarette per day do within 6 month prior Screening Subjects may positive alcohol breath test urine drug screen Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Lacosamide</keyword>
	<keyword>Vimpat</keyword>
	<keyword>Cognition</keyword>
	<keyword>Mental Processes</keyword>
	<keyword>Adverse Effects</keyword>
</DOC>